Clinical Trial Update: Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial at Emory University is identifying treatment concentrations for Defactinib and VS-6766 in patients with glioblastoma. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Defactinib (defactinib)
• VS-6766 (VS-6766)

Snippet

Sponsor: Emory University | Conditions: Glioblastoma, Recurrent Glioblastoma | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING